ClinicalTrials.gg
CompletedNCT05624853Updated Oct 23, 2023

A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain

A Phase 4 interventional study of pregabalin sustained release tablet and pregabalin immediate release capsule in Neuropathic Pain and Diabetes Mellitus, Type 2, sponsored by Yuhan Corporation. Completed at 8 sites in Korea, Republic of. Open to participants aged 19 Years to 74 Years. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Yuhan Corporation · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled May 2020, registered Nov 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
19 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing pregabalin in Neuralgia — 4 open to participants now, 4 under way, 1 of them phase 3. Pregabalin · Neuralgia.

Enrollment
19th of 50
130 · median 109
Started
2020
the only one that year
Phase 4
12 of 50
none open now
Registered
45th of 50
by date
Lead sponsor
2 of 50
Yuhan Corporation

Among the 50 studies testing pregabalin in Neuralgia, this one is the 19th largest by enrollment, is the only one that started in 2020, is one of 12 in phase 4, and was the 45th registered.

Neuralgia

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

Browse Neuralgia studies →

Open to participants now

4 of the 50 studies testing pregabalin in Neuralgia are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 19 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing pregabalin in Neuralgia, or all of them as a file.
02

Study summary

This study is to compare the efficacy and safety of pregabalin sustained release tablet and pregabalin immediate release capsule in type II diabetic patients with peripheral neuropathic pain.

03

Conditions studied

  • Neuropathic Pain
  • Diabetes Mellitus, Type 2

Keywords

  • pregabalin sustained release tablet
04

Who can participate

Ages eligible
19 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 19 years, \< 75 years
  2. VAS score for diabetic peripheral neuropathy pain ≥ 30
  3. Patients who have been administering pregabalin immediate release capsule 150 mg/day for more than 4 weeks
  4. Type II DM patient and ≤ 10 %
  5. Written

Exclusion criteria

Exclusion Criteria:

  1. Patient with to pregabalin
  2. Patient on anti-epileptic drugs
  3. Patients with pain caused by other factors than diabetic peripheral neuropathy
  4. Patients undergoing \<30 mL/min/1.73 m2 (MDRD) at screening
  5. (Aspartate Aminotransferase) or ALT(Alanine Aminotransferase) level ≥ 3x (upper limit of normal range) or active liver disease
  6. Drug-abusing patient
  7. Severe depression or uncontrolled abnormal mood and behavioral changes
  8. Pregnant and breast-feeding woman
  9. Patients who participated in other clinical trials for products within 30 days of screening
  10. Patients deemed to be ineligible to participate in the trial by investigator
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    pregabalin sustained release tablet

    pregabalin sustained release tablet 150mg qd for 8weeks

    Drug: pregabalin sustained release tablet

  • Active comparator
    pregabalin immediate release capsule

    pregabalin immediate release capsule 75mg bid for 8weeks

    Drug: pregabalin immediate release capsule

Interventions

  • pregabalin sustained release tablet 150mg qd for 8weeks

  • Drugpregabalin immediate release capsule

    pregabalin immediate release capsule 75mg bid for 8weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline to week 8 in Visual Analogue Scale(VAS)

    Time frame: Baseline/Week 8

Secondary outcomes

  1. Change from baseline to week 8 in Quality of Life(EQ-5D)

    Time frame: Baseline/Week 8

  2. Change from baseline to week 8 in Patients Global Impression of Change(PGIC)

    Time frame: Baseline/Week 8

  3. Change from baseline to week 8 in Clinician Global Impression of Change(CGIC)

    Time frame: Baseline/Week 8

  4. Change from baseline to week 8 in Daily Sleep Interference Scale(DSIS)

    Time frame: Baseline/Week 8

  5. Change from baseline to week 8 in Morisky Medication Adherence Scale 8-item version(MMAS-8)

    Time frame: Baseline/Week 8

  6. Dose and frequency of Rescue medication(Acetaminophen)

    Time frame: Baseline/Week 8

  7. Number and proportion of subjects with adverse event

    Time frame: Baseline/Week 8

07

Study locations

8 sites
  • Chungbuk National University Hospital
    Cheongju, Chungcheongbuk-do 28644, Korea, Republic of
  • Dankook University Hospital
    Cheonan, Chungcheongnam-do 31116, Korea, Republic of
  • Catholic University of Korea's Bucheon St. Mary's Hospital
    Bucheon, Gyeonggi-do 14647, Korea, Republic of
  • Inje University Haeundae Paik Hospital
    Busan, 48108, Korea, Republic of
  • Kosin University Gospel Hospital
    Busan, 49267, Korea, Republic of
  • Chungnam National University Hospital
    Daejeon, 35015, Korea, Republic of
  • Daejeon Eulji Medical Center, Eulji University
    Daejeon, 35233, Korea, Republic of
  • Chungnam National University Sejong Hospital
    Sejong, 30099, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Dec 2022, 31 months.

Of 22 phase 4 interventional studies under Neuralgia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 33. This study's 31 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2022
First posted
Nov 22, 2022
StartActual
May 12, 2020
Primary completionActual
Dec 20, 2022
CompletionActual
Dec 20, 2022
Last update
Oct 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05624853
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Nov 22, 2022
Start date
May 12, 2020
Primary completion
Dec 20, 2022
Completion
Dec 20, 2022
Last update
Oct 23, 2023

Study contacts

Bon Jeong Ku
principal investigator · Chungnam National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion